Arabic Arabic English English French French German German
dark

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

HUTCHMED Limited announces that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to HMPL-523, a novel, investigational spleen tyrosine kinase inhibitor, for the treatment of chronic adult primary immune thrombocytopenia patients who have received at least one prior therapy. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

40% of eligible population have had boosters; 28 community cases; 2 deaths; 31 people in hospital; two in ICU

Next Post

The unexpected benefits of fat in type 2 diabetes

Related Posts
Total
0
Share